Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Clinical utility of aromatase inhibitors as adjuvant treatment in postmenopausal early breast cancer.

Loaiza-Bonilla A, Socola F, Gl├╝ck S.

Clin Med Insights Womens Health. 2013 Jan 22;6:1-11. doi: 10.4137/CMWH.S8692. eCollection 2013. Review.

2.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

3.
4.

The role of aromatase inhibitors in early breast cancer.

Chung CT, Carlson RW.

Curr Treat Options Oncol. 2003 Apr;4(2):133-40. Review.

PMID:
12594939
5.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
6.
7.

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

Gibson LJ, Dawson C, Lawrence DH, Bliss JM.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003370. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD003370.

PMID:
17253488
8.

Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.

Carlson RW, Hudis CA, Pritchard KI; National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines in Oncology; American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors; St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer.

J Natl Compr Canc Netw. 2006 Nov;4(10):971-9. Review.

PMID:
17112447
9.
11.
13.

Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.

Carpenter R.

Eur J Surg Oncol. 2008 Jul;34(7):746-55. doi: 10.1016/j.ejso.2008.01.011. Epub 2008 Mar 4. Review.

PMID:
18296017
14.

[Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].

Mauriac L, Blanc-Vincent MP, Luporsi E, Cutuli B, Fourquet A, Garbay JR, Giard S, Spyratos F, Zafrani B, Dilhuydy JM.

Bull Cancer. 2000 Jun;87(6):469-90. Review. French.

PMID:
10903789
15.

Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.

Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ.

J Clin Oncol. 2005 Aug 1;23(22):5178-87. Epub 2005 Jul 5.

17.

Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.

Gradishar WJ.

Oncology. 2005;69(1):1-9. Epub 2005 Jul 28. Review.

PMID:
16088229
19.

Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

Carlson RW, Henderson IC.

Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. Review.

PMID:
14535531
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk